Seattle Cancer Care Alliance (SCCA) announced today that the American Academy of Nursing has selected Kathleen Shannon Dorcy, PhD, RN, Director, Clinical Nursing Research, Education and Practice, as an Academy Fellow.
Dr. Amanda Paulovich of Fred Hutch will lead a multi-institution effort to develop a biological test to predict which treatments will work for patients with ovarian cancer. Photos, video available: http://www.fredhutch.org/en/news/media-relations/bios-photos/paulovich-amanda/photos-graphics-video.html
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard therapies and adverse events leading to therapy discontinuation. A study at The University of Texas MD Anderson Cancer Center revealed new information about how the biomarkers retinoblastoma protein (Rb) and cytoplasmic cyclin E could indicate which patients will respond best to current first-line therapies.
A Fred Hutchinson Cancer Research Center study, led by epidemiologist Dr. Parveen Bhatti, found that night shift work is associated with reduced ability to repair DNA lesions. Over time, DNA damage that is not repaired will cause mutations that can lead to cancer.
$1 million CRI Technology Impact Award will support UPENN investigator's development of microchip-based research models that mimic human cancer and immune cell interactions
Until recently, melanomas that had spread to the brain could only be treated with surgery and radiation therapy. And even with treatment, patients typically lived only a median of four months. However, patients like Kathy Roberts now have alternatives. After having surgery to repair the damage from the tumors in her ankle, her doctors encouraged her to enroll in a clinical trial of immunotherapy for patients with melanoma brain tumors at Georgetown Lombardi Comprehensive Cancer Center, which she did.
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D., and his wife, Charlene, of Athens, Ohio, are paving the way for future scientists to do the same with a transformative $10.5 million gift to The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.
Nation's largest Powwow and health screening
New Division Director of Medical Oncology Announced
Women who receive human papillomavirus (HPV) testing, in addition to a pap smear, receive a faster, more complete diagnosis of possible cervical precancer, according to a study of over 450,000 women by Queen Mary University of London (QMUL) and the University of New Mexico (UNM) Comprehensive Cancer Center.
St. Jude Children’s Research Hospital and Fred Hutchinson Cancer Research Center have developed an algorithm that predicts T cell recognition of antigens and sets the stage to more effectively harness the immune system
CRI's 2017 Immunotherapy Patient Summit Series will travel to five U.S. cities to provide free educational programming designed for cancer patients and caregivers who are seeking to learn more about cancer immunotherapy and clinical trials.
As published in JNCCN, a Siteman Cancer Center study uncovered potential to significantly improve NCCN Guidelines-concordant care in patients with early-stage breast cancer.
A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the immune effects of high-dose radiation therapy followed by surgery in patients with advanced kidney cancer may also set the stage for combination treatments with immunotherapy.
Despite legislation prohibiting the use of ultraviolet (UV) indoor tanning facilities by minors, one in every five tanning salons in United States where such bans are in place stated over the phone that they would allow an underage caller to do so.
A $2.24 million competing renewal grant from the National Cancer Institute will support the work of investigators at Rutgers Cancer Institute of New Jersey and Princeton University to learn more about the fuel required for tumor growth. The collaborative research will focus on melanomas and lung cancers caused by mutations in genes known as K-ras and Braf.
Among long-term colorectal cancer survivors, use of nonsteroidal anti-inflammatory drugs, or NSAIDs, is associated with about a 25 percent reduction in all-cause mortality, according to new research from Fred Hutchinson Cancer Research Center.
Researchers studying a DNA-cutting enzyme with a crucial role in regulating the structure of genes have discovered a broad role for its cutting activity in driving abnormal genetic rearrangements called translocations that cause cancer, including leukemias and solid tumors. The findings open possibilities for new clinical approaches.
Ongoing clinical trial by University of Colorado Cancer Center investigators is evaluating the ability of an inhaled form of the pulmonary hypertension drug iloprost to prevent lung cancer.
New research could make treatment for gastrointestinal cancers safer.
The investigation found that the drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway discovered by Pagano’s group.
Can use of hair products have an impact on breast cancer risk for women? That is a question explored by investigators from Rutgers Cancer Institute of New Jersey, Rutgers School of Public Health and other colleagues who examined use of hair dyes, hair relaxers and cholesterol-based hair products in African-American and Caucasian women.
The Association of American Cancer Institutes applauds the appointment of Norman “Ned” Sharpless, MD, as the next director of the National Cancer Institute. Dr. Sharpless is an AACI board member and director of the University of North Carolina Lineberger Comprehensive Cancer Center, an AACI member.
Peter Kanetsky, Ph.D., M.P.H., chair of the Cancer Epidemiology Department at Moffitt Cancer Center, and colleagues from the International TEsticular CAncer Consortium (TECAC), launched a large analysis of five major testicular cancer studies to investigate genetic risk factors linked to TGCT. Their results, which uncovered eight new genetic markers associated with TGCT, were published in the June 12 issue of Nature Genetics.
In a study published today in Cancer Cell, Moffitt Cancer Center researchers report that a newly discovered epigenetic mechanism can lead to the development of castration-resistant prostate cancer. They identified a novel drug that targets this epigenetic mechanism and may be able to combat the deadly form of the disease.
University of Colorado Cancer Center study pinpoints promising link in the chain of hedgehog signaling that, when broken, could reduce the metastatic potential of breast cancer.
The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new radiation technology aimed at reducing side effects of standard radiation including unwanted radiation to healthy tissue.
The latest HPV vaccine could prevent most HPV infections — and millions of cancers — worldwide, according to an article by Cosette Wheeler, PhD, and her collaborators. The article describing the HPV vaccine and strategies to overcome issues with its use was published online by the American Society of Clinical Oncology.
The latest in childhood cancer statistics in New Jersey show significant declines in mortality rates for white, black and Hispanic children from 1979 to 2013. A Rutgers Cancer Institute of New Jersey expert says this improvement in survival can be attributed to treatment advances and participation in clinical trials.
While the risk of developing testicular cancer is low, every man should understand some basic facts about this disease. Rutgers Cancer Institute of New Jersey experts share more about the disease, which is the most common malignancy among men ages 15 to 35.
An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are inherently slow growing, according to Yale Cancer Center experts.
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at The University of Texas MD Anderson Cancer Center.
In updated findings from the KEYNOTE-059 trial of pembrolizumab in advanced gastric or gastroesophageal junction (GEJ) cancer, the PD-1 inhibitor maintained signs of its clinical benefit in this patient population.
Walking is probably the simplest, easiest and the most inexpensive way to remain fit. Experts link a bevy of health benefits with regular walking.
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered into an agreement to collaborate on research for a unique randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck.
Day-long endurance event starting at the U.S. Military Academy at West Point, NY, focused on cancer immunotherapy research
The University of Kansas Cancer Center and Children’s Mercy Twitter #NoTobaccoChat focused on changing the way healthcare providers treat tobacco dependence.
Dr. Philip McCarthy of Roswell Park Cancer Institute presents updated findings on CALGB/ECOG 100104 study of lenalidomide maintenance therapy for multiple myeloma, adjusting data to account for crossover effect.
Dr. Kunle Odunsi of Roswell Park Cancer Institute presented an update about an ongoing clinical trial involving T-cell engineering to treat advanced ovarian cancer at the ASCO Annual Meeting in Chicago.
Roswell Park and OmniSeq report that a custom algorithm they developed based on a 54-gene signature accurately predicted response to anti-PD-L1 treatment in 90% of the cases they analyzed.
The authors of a phase II clinical study report that combination therapy with brentuximab vedotin and gemcitabine in patients is “highly active" regimen for patients with Hodgkin lymphoma.
For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life for cancer patients in the United States because of successful therapies that were proved through its trials.That is the conclusion of an analysis, led by a faculty member at Fred Hutchinson Cancer Research Center, of outcomes data from 193 randomized Phase III clinical trials tested by SWOG.
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 annual meeting of the American Society of Clinical Oncology.
A recent study by Yale Cancer Center researchers revealed a 41% response to the antibody drug, enfortumab vedotin, by metastatic urothelial (mUC) tumors in a phase I clinical trial
In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.
Worldwide phase II clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 show the promise of the second-generation drug dasatinib against pediatric CML. Of 113 pediatric patients studied, 75 percent of patients who had previously failed or did not tolerate imatinib saw progression-free survival 48 months after starting treatment with dasatinib.
Study presented at ASCO 2017 shows that only 9 percent of 259 evaluated AML patients received all seven of the NCCN-recommended genetic tests.
A combination regimen of two immunotherapies and another of two targeted therapies each significantly shrank metastatic brain tumors in at least 50 percent of patients in separate multi-center clinical trials presented today at the 2017 ASCO Annual Meeting by principal investigators from The University of Texas MD Anderson Cancer Center.
Updated results of a clinical trial that launched in 2007 were presented today by Ethan Basch, MD, of Memorial Sloan Kettering Cancer Center (MSK) and UNC Lineberger Comprehensive Cancer Center, at the annual meeting of the American Society of Clinical Oncology. Data showed that systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes (PROs) improved overall survival.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right